Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication

A Borghetti, G Baldin, F Lombardi, A Ciccullo, A Capetti, S Rusconi, G Sterrantino, A Latini, M V Cossu, R Gagliardini, A De Luca, S Di Giambenedetto

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: We evaluated the efficacy and tolerability of lamivudine + dolutegravir in a cohort of HIV-1 infected, treatment-experienced patients with undetectable HIV-RNA.

METHODS: Time to treatment discontinuation (TD) and virological failure (VF) and their predictors were assessed in a multicenter cohort of HIV-1 infected patients, starting lamivudine + dolutegravir after reaching viral suppression. Secondary objective was the evaluation of changes in lipid profile, renal and immunological functions at week 48.

RESULTS: We enrolled 206 patients (72.8% male, with 51 years median age), who mainly switched their antiretroviral therapy for simplification (32.5%) or drug toxicity (54.5%). The estimated probability of maintaining virological suppression at 48 and 96 weeks was 98.2% and 95.1%, respectively. VF was independently predicted by cumulative time on antiretroviral therapy. The estimated probability of remaining on lamivudine plus dolutegravir was 86.7% and 80.5% at week 48 and 96, respectively. A significant improvement in immunological function (CD4 count and CD4/CD8 ratio) was evidenced at week 48, as well as a decrease in total cholesterol/HDL ratio, triglycerides and estimated glomerular filtration rate.

CONCLUSIONS: Lamivudine plus dolutegravir was effective in maintaining viral suppression in our cohort and led to an improvement in metabolic and immunologic functions.

Original languageEnglish
Pages (from-to)452-454
Number of pages3
JournalHIV Medicine
Volume19
Issue number7
DOIs
Publication statusPublished - Aug 2018

Fingerprint

Lamivudine
HIV-1
CD4-CD8 Ratio
Therapeutics
CD4 Lymphocyte Count
Drug-Related Side Effects and Adverse Reactions
Glomerular Filtration Rate
HDL Cholesterol
Triglycerides
HIV
RNA
Kidney
Lipids
dolutegravir

Cite this

Borghetti, A., Baldin, G., Lombardi, F., Ciccullo, A., Capetti, A., Rusconi, S., ... Di Giambenedetto, S. (2018). Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV Medicine, 19(7), 452-454. https://doi.org/10.1111/hiv.12611

Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. / Borghetti, A; Baldin, G; Lombardi, F; Ciccullo, A; Capetti, A; Rusconi, S; Sterrantino, G; Latini, A; Cossu, M V; Gagliardini, R; De Luca, A; Di Giambenedetto, S.

In: HIV Medicine, Vol. 19, No. 7, 08.2018, p. 452-454.

Research output: Contribution to journalArticle

Borghetti, A, Baldin, G, Lombardi, F, Ciccullo, A, Capetti, A, Rusconi, S, Sterrantino, G, Latini, A, Cossu, MV, Gagliardini, R, De Luca, A & Di Giambenedetto, S 2018, 'Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication', HIV Medicine, vol. 19, no. 7, pp. 452-454. https://doi.org/10.1111/hiv.12611
Borghetti, A ; Baldin, G ; Lombardi, F ; Ciccullo, A ; Capetti, A ; Rusconi, S ; Sterrantino, G ; Latini, A ; Cossu, M V ; Gagliardini, R ; De Luca, A ; Di Giambenedetto, S. / Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. In: HIV Medicine. 2018 ; Vol. 19, No. 7. pp. 452-454.
@article{4aeb08b6541e49c2b418a5c03fdd6e1f,
title = "Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication",
abstract = "OBJECTIVES: We evaluated the efficacy and tolerability of lamivudine + dolutegravir in a cohort of HIV-1 infected, treatment-experienced patients with undetectable HIV-RNA.METHODS: Time to treatment discontinuation (TD) and virological failure (VF) and their predictors were assessed in a multicenter cohort of HIV-1 infected patients, starting lamivudine + dolutegravir after reaching viral suppression. Secondary objective was the evaluation of changes in lipid profile, renal and immunological functions at week 48.RESULTS: We enrolled 206 patients (72.8{\%} male, with 51 years median age), who mainly switched their antiretroviral therapy for simplification (32.5{\%}) or drug toxicity (54.5{\%}). The estimated probability of maintaining virological suppression at 48 and 96 weeks was 98.2{\%} and 95.1{\%}, respectively. VF was independently predicted by cumulative time on antiretroviral therapy. The estimated probability of remaining on lamivudine plus dolutegravir was 86.7{\%} and 80.5{\%} at week 48 and 96, respectively. A significant improvement in immunological function (CD4 count and CD4/CD8 ratio) was evidenced at week 48, as well as a decrease in total cholesterol/HDL ratio, triglycerides and estimated glomerular filtration rate.CONCLUSIONS: Lamivudine plus dolutegravir was effective in maintaining viral suppression in our cohort and led to an improvement in metabolic and immunologic functions.",
author = "A Borghetti and G Baldin and F Lombardi and A Ciccullo and A Capetti and S Rusconi and G Sterrantino and A Latini and Cossu, {M V} and R Gagliardini and {De Luca}, A and {Di Giambenedetto}, S",
note = "{\circledC} 2018 British HIV Association.",
year = "2018",
month = "8",
doi = "10.1111/hiv.12611",
language = "English",
volume = "19",
pages = "452--454",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Blackwell Publishing Ltd",
number = "7",

}

TY - JOUR

T1 - Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication

AU - Borghetti, A

AU - Baldin, G

AU - Lombardi, F

AU - Ciccullo, A

AU - Capetti, A

AU - Rusconi, S

AU - Sterrantino, G

AU - Latini, A

AU - Cossu, M V

AU - Gagliardini, R

AU - De Luca, A

AU - Di Giambenedetto, S

N1 - © 2018 British HIV Association.

PY - 2018/8

Y1 - 2018/8

N2 - OBJECTIVES: We evaluated the efficacy and tolerability of lamivudine + dolutegravir in a cohort of HIV-1 infected, treatment-experienced patients with undetectable HIV-RNA.METHODS: Time to treatment discontinuation (TD) and virological failure (VF) and their predictors were assessed in a multicenter cohort of HIV-1 infected patients, starting lamivudine + dolutegravir after reaching viral suppression. Secondary objective was the evaluation of changes in lipid profile, renal and immunological functions at week 48.RESULTS: We enrolled 206 patients (72.8% male, with 51 years median age), who mainly switched their antiretroviral therapy for simplification (32.5%) or drug toxicity (54.5%). The estimated probability of maintaining virological suppression at 48 and 96 weeks was 98.2% and 95.1%, respectively. VF was independently predicted by cumulative time on antiretroviral therapy. The estimated probability of remaining on lamivudine plus dolutegravir was 86.7% and 80.5% at week 48 and 96, respectively. A significant improvement in immunological function (CD4 count and CD4/CD8 ratio) was evidenced at week 48, as well as a decrease in total cholesterol/HDL ratio, triglycerides and estimated glomerular filtration rate.CONCLUSIONS: Lamivudine plus dolutegravir was effective in maintaining viral suppression in our cohort and led to an improvement in metabolic and immunologic functions.

AB - OBJECTIVES: We evaluated the efficacy and tolerability of lamivudine + dolutegravir in a cohort of HIV-1 infected, treatment-experienced patients with undetectable HIV-RNA.METHODS: Time to treatment discontinuation (TD) and virological failure (VF) and their predictors were assessed in a multicenter cohort of HIV-1 infected patients, starting lamivudine + dolutegravir after reaching viral suppression. Secondary objective was the evaluation of changes in lipid profile, renal and immunological functions at week 48.RESULTS: We enrolled 206 patients (72.8% male, with 51 years median age), who mainly switched their antiretroviral therapy for simplification (32.5%) or drug toxicity (54.5%). The estimated probability of maintaining virological suppression at 48 and 96 weeks was 98.2% and 95.1%, respectively. VF was independently predicted by cumulative time on antiretroviral therapy. The estimated probability of remaining on lamivudine plus dolutegravir was 86.7% and 80.5% at week 48 and 96, respectively. A significant improvement in immunological function (CD4 count and CD4/CD8 ratio) was evidenced at week 48, as well as a decrease in total cholesterol/HDL ratio, triglycerides and estimated glomerular filtration rate.CONCLUSIONS: Lamivudine plus dolutegravir was effective in maintaining viral suppression in our cohort and led to an improvement in metabolic and immunologic functions.

U2 - 10.1111/hiv.12611

DO - 10.1111/hiv.12611

M3 - Article

C2 - 29573320

VL - 19

SP - 452

EP - 454

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 7

ER -